MRMario Giorgio Rizzone

Mario Giorgio Rizzone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mario Giorgio Rizzone has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Theta‐Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial

    by Gabriele Imbalzano, Elisa Montanaro, Claudia Ledda, Francesca Donetto, Francesco D'ANgelo, Corrado Campisi, Carlo Alberto Artusi, Alberto Romagnolo, Mario Giorgio Rizzone, Marco Bozzali, et al.

    Background: High‐frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves Parkinson's disease (PD) motor symptoms but may deteriorate verbal fluency (VF). Theta stimulation showed potential cognitive benefits associated with motor worsening.Objectives: This randomized, double‐blind, crossover study evaluated the efficacy and safety of combined theta‐gamma frequency stimulation on VF in PD patients with STN‐DBS.Methods: Patients were randomized 1:1 for standard or theta‐gamma stimulation. VF, motor, and non‐motor symptoms were assessed at baseline, 1 h, and 1 month after each period. Data were analyzed using a linear mixed‐effects model.Results: Twelve patients completed the study. Non‐episodic (P = 0.038) and episodic VF (P = 0.030) improved after 1 month of theta‐gamma stimulation, while phonemic and switching fluency were unchanged. Motor and non‐motor outcomes were unaffected by the stimulation, with mild adverse events.Conclusion: Combined theta‐gamma stimulation may enhance VF in PD patients with STN‐DBS without worsening motor symptoms or safety concerns. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial

    by Carlo Alberto Artusi, Claudia Ledda, Silvia Gallo, Domiziana Rinaldi, Corrado Campisi, Vanessa Rousseau, Claire Thalamas, Raquel Barbosa, Fabienne Ory-Magne, Christine Brefel-Courbon, et al.

    Background: Freezing of gait (FoG) is a debilitating symptom of Parkinson's disease (PD) with limited response to dopaminergic medication and subthalamic deep brain stimulation (STN-DBS). Substantia nigra pars reticulata (SNr) stimulation could improve FoG. Objective: To analyze the effect of combined STN-SNr stimulation at different frequencies on FoG. Methods: We performed a double-blind, cross-over, randomized pilot trial involving STN-DBS treated PD patients with FoG. Participants received: high-frequency (HF) STN-DBS (S), combined HF-STN and SNr stimulation (C1), and combined HF-STN and low-frequency (LF) SNr stimulation (C2), for one month each. The primary endpoint was the score change in the New-Freezing-of-Gait-Questionnaire (NFOG-Q). Secondary analyses were performed on motor complications, axial symptoms, daily living activities, psychiatric symptoms, sleep, and patient preference. Results: Fifteen patients received at least one combined stimulation. No significant difference in NFOG-Q scores was found between S, C1, and C2; one-third of patients showed a clinically significant improvement (≥8 points) with combined stimulations. Motor complications improved significantly with C1 and C2 (C1-S: 3.6 ± 3.8 vs. 4.9 ± 3.8, p = 0.046; C2-S: 2.7 ± 3.1 vs. 4.9 ± 3.8, p = 0.005). 80% of patients preferred the combined STN-SNr stimulation while blinded. All adverse events were manageable. Conclusions: Our study did not prove a statistically significant improvement in NFOG-Q with STN-SNr stimulation; however, one-third of patients experienced a clinically meaningful FoG improvement, and the majority preferred to maintain STN-SNr stimulation. STN-SNr stimulation was both safe and effective in addressing motor complications and improving sleep quality, highlighting the importance of further exploration into the effects of combined STN-SNr stimulation.


  • Parkinson’s Disease

    by Mario G. Rizzone, Leonardo Lopiano, Elena Vittoria Longhi


  • Open Access

    Social cognition deficits in amyotrophic lateral sclerosis: A pilot cross‐sectional population‐based study

    by Francesca Palumbo, Barbara Iazzolino, Laura Peotta, Antonio Canosa, Umberto Manera, Maurizio Grassano, Federico Casale, Giorgio Pellegrino, Mario Giorgio Rizzone, Rosario Vasta, et al.

    Background and purpose: Social cognition (SC) deficits are included in amyotrophic lateral sclerosis (ALS)–frontotemporal spectrum disorder revised diagnostic criteria. However, SC performance among ALS patients is heterogeneous due to the phenotypic variability of the disease and the wide range of neuropsychological tools employed. The aim of the present study was to assess facial emotion recognition and theory of mind in ALS patients compared to controls and to evaluate correlations with the other cognitive domains and degree of motor impairment.Methods: Eighty‐three patients and 42 controls underwent a cognitive evaluation and SC assessment through the Ekman 60 Faces Test (EK‐60F), the Reading the Mind in the Eyes Test–36 Faces (RMET‐36), and the Story‐Based Empathy Task (SET).Results: ALS patients showed significantly worse performance compared to controls in EK‐60F global score (p < 0.001), recognition of disgust (p = 0.032), anger (p = 0.038), fear (p < 0.001), and sadness (p < 0.001); RMET‐36 (p < 0.001), and SET global score (p < 0.001). Also, cognitively normal patients (ALS‐CN) showed significantly worse performance compared to controls in EK‐60F global score (p < 0.001), recognition of fear (p = 0.002), sadness (p < 0.001), and SET (p < 0.001). RMET‐36 showed a significant correlation with the Category Fluency Test (p = 0.041). SC tests showed no correlation with motor impairment expressed by Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised.Conclusions: ALS patients, also when categorized as ALS‐CN, may show impairment in SC performance. The frequent identification of early SC impairment in ALS patients supports the need to routinely assess SC for its impact on end‐of‐life decisions and its potential influence on patients' quality of life.


  • Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease

    by Mario Giorgio Rizzone, Francesca Mancini, Carlo Alberto Artusi, Roberta Balestrino, Salvatore Bonvegna, Margherita Fabbri, Gabriele Imbalzano, Elisa Montanaro, Alberto Romagnolo, Maurizio Zibetti, et al.

    Background Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective surgical treatment for advanced Parkinson’s disease (PD). However, some patients still experience motor fluctuations or dyskinesia after STN-DBS. Safinamide is approved as add-on treatment to levodopa in fluctuating PD patients. In this study, we evaluated the effect of safinamide as adjunctive therapy in PD patients still experiencing motor fluctuations and dyskinesias after STN-DBS. Methods PD patients treated for at least 2 years with bilateral STN-DBST and with troublesome motor fluctuation and/or dyskinesias were examined by means of the Movement Disorders Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the quality of life questionnaire Parkinson’s Disease Questionnaire-8 (PDQ-8) and the Non-Motor Symptoms Scale (NMSS) at baseline (T0), after 1 month of treatment with safinamide 50 mg daily (T1) and after another month of treatment with safinamide 100 mg daily (T2). Results Twenty-nine PD patients were examined. An improvement of the MDS-UPDRS IV score (motor complications) was observed between T0 and T1, T0 and T2, and T1 and T2. The time spent in the OFF state, the functional impact and the complexity of motor fluctuations significantly improved between T0 and T1 and T0 and T2. The mean levodopa equivalent daily dose significantly decreased from T0 to T1 and from T0 to T2. Regarding non-motor symptoms, an improvement on mood and pain was observed. Conclusions Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain.


  • Should We Consider Deep Brain Stimulation Discontinuation in Late‐Stage Parkinson's Disease?

    by Margherita Fabbri, Maurizio Zibetti, Mario Giorgio Rizzone, Giulia Giannini, Linda Borellini, Alessandro Stefani, Francesco Bove, Andrea Bruno, Giovanna Calandra‐Buonaura, Nicola Modugno, et al.

    Background: Subthalamic deep brain stimulation (STN‐DBS) effects may decrease with Parkinson's disease (PD) progression. There is no indication if, when, and how to consider the interruption of DBS treatment in late‐stage PD. The objective of the current study was to investigate the percentage of “poor stimulation responders” among late‐stage PD patients for elaborating an algorithm to decide whether and when DBS discontinuation may be considered.Methods: Late‐stage PD patients (Hoehn Yahr stage ≥4 and Schwab and England Scale <50 in medication on/stimulation on condition) treated with STN‐DBS for at least 5 years underwent a crossover, double‐blind, randomized evaluation of acute effects of stimulation. Physicians, caregivers, and patients were blinded to stimulation conditions. Poor stimulation responders (MDS‐UPDRS part III change <10% between stimulation on/medication off and stimulation off/medication off) maintained the stimulation off/medication on condition for 1 month for open‐label assessment.Results: Thirty‐six patients were included. The acute effect of stimulation was significant (17% MDS‐UPDRS part III), with 80% of patients classified as “good responders.” Seven patients were classified as “poor stimulation responders,” and the stimulation was switched off, but in 4 cases the stimulation was switched back “on” because of worsening of parkinsonism and dysphagia with a variable time delay (up to 10 days). No serious adverse effects occurred.Conclusions: The vast majority of late‐stage PD patients (92%) show a meaningful response to STN‐DBS. Effects of stimulation may take days to disappear after its discontinuation. We present a safe and effective decisional algorithm that could guide physicians and caregivers in making challenging therapeutic decisions in late‐stage PD. © 2020 International Parkinson and Movement Disorder Society


  • Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?

    by Margherita Fabbri, Maurizio Zibetti, Giulia Ferrero, Anna Accornero, Isabel Guimaraes, Mario Giorgio Rizzone, Alberto Romagnolo, Joaquim J. Ferreira, Leonardo Lopiano


  • Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease

    by Mario Giorgio Rizzone, Tiziana Martone, Roberta Balestrino, Leonardo Lopiano


  • Open Access

    Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?

    by M.G. Rizzone, A. Fasano, A. Daniele, M. Zibetti, A. Merola, L. Rizzi, C. Piano, C. Piccininni, L.M. Romito, L. Lopiano, et al.